

Press Release – Basel, Switzerland December 13th 2006

Expansion of Genedata's Collaboration with Serono into High Content Screening

Computational biology firm Genedata announces the expansion of its screening analysis collaboration with Serono. Scientists at Serono now use Genedata's computational solution to combine results from high content screening assays with chemical and pharmacological information as part of the process to identify promising candidates for drug development.

High content data from cellular assay technologies used at Serono enable sophisticated biological profiling. These screening technologies provide insights into the biological effects of potential drug candidates, including possible toxic side effects.

To exploit these technologies, screening results need to be shared among people with different expertise, including chemists and toxicologists. Biopharmaceutical company Serono is familiar with this process, and is organized internally to ensure there is good communication between various expert groups.

To complement this process, Genedata's result management and analysis solution Genedata Screener® combines central database functions with interactive analysis tools and web-based access to databases. In step with recent developments in biomolecular screening, Genedata have developed a scientific platform to validate and analyze cellular assays.

During the course of the collaboration, Genedata extended its Screener solution, enabling Serono's researchers to analyze and annotate their screening results more efficiently. The collaboration quickly reached the point where the software was a precise fit with Serono's needs.

Scientists from Serono and Genedata co-authored a research presentation made at this year's Society for Biomolecular Sciences annual meeting in Seattle, Washington. Genedata plays an important role in the exchange of knowledge at Serono, both internally and with the wider screening community.

The collaboration has progressed in stages since its initiation in 2003. In its current form, Genedata's solution is compatible with Cellomics screening technologies and includes sophisticated Application Programming Interfaces (APIs), an important technology for web-based software applications.

Dr. Stephan Heyse, Head of Genedata Screener, explained, "We are very pleased with the way our solution has been adopted at Serono, not just within Serono's IT department, but also in terms of integration with the company's drug discovery processes".

Contact

Genedata AG
Dr. Tobe Freeman
Head, Public Relations
Phone +41 61 697 8510
Fax +41 61 697 7244
tobe.freeman@genedata.com
www.genedata.com

Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data. Genedata Screener® for high throughput screening analysis. And Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Munich (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Japan, Taiwan and Singapore. For more information about Genedata, please visit: www.genedata.com.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.